Enhabit, Inc. (EHAB)
(Delayed Data from NYSE)
$8.29 USD
-1.41 (-14.54%)
Updated May 9, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
EHAB 8.29 -1.41(-14.54%)
Will EHAB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EHAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EHAB
Enhabit (EHAB) Beats Q1 Earnings Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
EHAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enhabit (EHAB) Lags Q3 Earnings and Revenue Estimates
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate Enhabit (EHAB) to Report a Decline in Earnings: What to Look Out for
Other News for EHAB
Leerink Partners Sticks to Its Sell Rating for Enhabit, Inc (EHAB)
AREX Capital Expresses Disappointment in Enhabit’s Strategic Review Conclusion
Enhabit falls -21.1%
AREX Capital expresses disappointment in Enhabit's strategic review findings
Enhabit challenged by hedge fund AREX Capital seeking seven board seats - report